Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||UNKNOWN / 1||- / -|
Administered by: Other Purchased by: ??
Symptoms: Cardiac failure, Cardiovascular disorder, Dyspnoea, Respiratory disorder, N-terminal prohormone brain natriuretic peptide increased
Life Threatening? Yes
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: BETMIGA; LETROZOL; LENDORMIN
Preexisting Conditions: Medical History/Concurrent Conditions: Breast cancer metastatic
Diagnostic Lab Data: Test Name: NTproBNP; Result Unstructured Data: Test Result:increased
CDC 'Split Type': BEPFIZER INC2021283186
Write-up: Dyspnoea; Decompensation cardiac; N-terminal prohormone brain natriuretic peptide increased; Respiratory disorder; Cardiovascular disorder; This is a spontaneous report from a contactable consumer downloaded from the Regulatory Authority-WEB BE-FAMHP-DHH-N2021-80173. A 97-year-old female patient received the first dose of bnt162b2 (COMIRNATY), via an unspecified route of administration at single dose on 18Jan2021 Lot Number: Unknown) for COVID-19 immunisation. Medical history included palliative metastatic breast cancer. Concomitant medications included mirabegron (BETMIGA), letrozol, brotizolam (LENDORMIN), all for an unspecified indication. On 20Jan2021, the patient experienced dyspnoea, decompensation cardiac, N-terminal prohormone brain natriuretic peptide increased, respiratory disorder, cardiovascular disorder. Therapeutic measures were taken as a result of the events included diuretics. The patient died on 03Feb2021. It was not reported if an autopsy was performed. Seriousness criteria of the events was reported as serious due to life threatening and death. Reporter Comment: Treatment - Yes Diuretics Evolution of the ADR - Deceased Examinations - Increased NTproBNP value ADR description - Acute dyspnoea, based on cardiac decompensation. No follow-up attempts are possible. No further information is expected. Information on batch/lot number cannot be obtained.; Reporter''s Comments: Treatment - Yes Diuretics Evolution of the ADR - Deceased Examinations - Increased NTproBNP value ADR description - Acute dyspnoea, based on cardiac decompensation; Reported Cause(s) of Death: Dyspnoea; Decompensation cardiac; N-terminal prohormone brain natriuretic peptide increased; Respiratory disorder; Cardiovascular disorder
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166